Slide 1: Building a Portfolio of Differentiated Specialty Therapies
For personal use only Building a Portfolio of Differentiated Specialty Therapies Investor Update | May 2026 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer ‣ Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd ‣ Forward looking statements: This presentation contains forward-looking information about the (Company or LTP) to provide general information about the Company. The information in
Slide 3: Executive Summary
Executive Summary LTR Pharma: Late-Stage Pharmaceutical Platform with Validated Early Market Access Differentiated Lead Program – SPONTAN / ROXUS For personal use only Rapid-acting intranasal PDE5 therapy demonstrating 5x faster absorption versus oral tablets at half the dose, with a validated safet
Slide 4: Market Inefficiency: High Discontinuation and Delayed Onset
For personal use only Market Inefficiency: High Discontinuation and Delayed Onset
Slide 5: Global Erectile Dysfunction Treatment Market
Global Erectile Dysfunction Treatment Market For personal use only Global ED drug market estimated at ~US$5B annually1 Oral PDE5 inhibitors currently dominate prescribing High discontinuation rates (>50%) reported with oral PDE5 inhibitors due to delayed onset, inconsistent response and tolerability
Slide 6: Understanding the Market Need
Understanding Physical causes Psychological Impact the Market Need ‣ Heart health ‣ Relationship problems ‣ Hormone balance ‣ Mental wellbeing A significant healthcare ‣ Prostate Cancer ‣ Day to day stress For personal use only challenge affecting ‣ Diabetes relationships and ‣ Medical treatments qu
Slide 7: Current Treatments: Oral PDE5 inhibitors and SPONTAN Nasal Spray
Current Treatments Oral PDE5 inhibitors and SPONTAN® Nasal Spray Oral Phosphodiesterase-5 (PDE5) Issues with oral For personal use only inhibitors are first-line treatments PDE5 inhibitors Product Main Time before sexual Approval Generic Does not work Brand(s) activity for dose Date (US) availabilit
Slide 8: Where SPONTAN Fits in the ED Treatment Landscape
Where SPONTAN Fits in the ED Treatment Landscape For personal use only Current first-line therapy: Oral PDE5 inhibitors (Viagra, Cialis, Levitra) Limitations of oral therapies include delayed onset, food interactions, and high discontinuation rates SPONTAN ® intranasal delivery bypasses first-pass m
Slide 9: Prevalence in Key Markets
Prevalence in Key Markets As risk factors become more prevalent, so does ED Global ~322m men by 2025 For personal use only USA China Aus EU 60.7% ~30m ~33m ~150m of males 45y/o+ Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023 9
Slide 10: Solution
For personal use only Solution
Slide 11: SPONTAN Phase I Pharmacokinetic Study
SPONTAN® Phase I Pharmacokinetic Study Rapid onset effect, consistent delivery and improved safety profile For personal use only ‣ SPONTAN® nasal spray achieved rapid absorption and Parameter Vardenafil faster onset of action compared to oral PDE5 inhibitors. (5mg) (10mg) oral ‣ SPONTAN® delivered s
Slide 12: SPONTAN the Science of Superior Delivery
SPONTAN® the Science of Superior Delivery Faster and more potent For personal use only Speed Superiority Healthcare Professional Insight ‣ Tmax: 5x faster than oral tablets Patients can respond in as little as 5 minutes, ‣ Peak concentration in as little as 9 mins well before peak concentration is r
Slide 13: Phase II Interim Data Reinforce Rapid-Onset Profile and Expand Dataset
Phase II Interim Data Reinforce Rapid-Onset Profile and Expand Dataset Key Highlights For personal use only Rapid Absorption Profile Consistent Pharmacokinetic Profile ‣ Median Tmax ~10 minutes for SPONTAN® (5 mg) ‣ Comparable PK observed across adult and ≥65-year cohorts in the ‣ Compared with ~60
Slide 14: Phase II Interim Pharmacokinetic Profile
Phase II Interim Pharmacokinetic Profile SPONTAN® vs Oral Comparator For personal use only Parameter Vardenafil 5 mg (Intranasal) 20 mg (Oral) ‣ Faster onset profile observed with intranasal SPONTAN® ‣ ~10 minutes (10–15 ‣ ~60 minutes (30–180 ‣ Median Tmax compared with oral vardenafil. min) min) ‣
Slide 15: Australian Early Access Program: Real-World Clinical and Prescriber Validation
Australian Early Access Program: Real-World Clinical and Prescriber Validation TGA Special Access Scheme - 1,000+ prescriptions For personal use only supporting real-world clinical and prescriber validation Prescriber Real-World Commercial Infrastructure Adoption Clinical Data Established ‣ 1,000+ p
Slide 16: Why LTR Pharma Can Win in the ED Treatment Market
Why LTR Pharma Can Win in the ED Treatment Market For personal use only Clinically differentiated product: SPONTAN demonstrates ~5x faster absorption versus oral PDE5 tablets Intranasal delivery bypasses first-pass metabolism, enabling rapid systemic exposure Real-world validation: 1,000+ prescripti
Slide 17: US Market Strategy
US Market Strategy Dual Pathway Approach For personal use only Primary Value Pathway – FDA 505(b)(2) FDA Regulatory ‣ Pre-IND meeting completed with FDA Program Check Points ‣ Agreed development framework ‣ Phase II PK study underway Pre-IND Meeting ‣ Single pivotal Phase III Safety and Efficacy stu
Slide 18: Portfolio Overview and Development Focus
Portfolio Overview and Development Lead Clinical Program ‣ TGA Early Access – ACTIVE Focus ‣ FDA 505(b)(2) regulatory pathway ‣ Phase II PK Study – interim data released For personal use only Intranasal Sprays for Erectile ‣ 503A Commercial Discussions Progressing Dysfunction Validated Platform Supp
Slide 19: Strategic Execution
For personal use only Strategic Execution Milestones, Partnerships and Regulatory Progress
Slide 20: Global Co-Development Agreement: Aptar Pharma
Global Co-Development Agreement Aptar Pharma Strategic partnership driving regulatory For personal use only success and market readiness Combination product expertise Regulatory and development Strategic significance ‣ Co-development agreement ‣ Extractables study completed ‣ Global supply and FDA e
Slide 21: Financial Position
Financial Position Disciplined capital management supporting clinical and commercial execution For personal use only Cash in Bank Quarterly Operation Cash Outflow Debt Position $24.1 million $1.8 million Zero debt Funded Value Inflection Points Completion of Phase II PK Study Human factors programme
Slide 22: Key Milestones
Key Milestones Executing across clinical, regulatory and commercial programmes For personal use only Achieved Near-Term Development Progression (H1 2026) (H2 2026+) ‣ Phase II PK interim data reported ‣ Human factors study completion ‣ Full Phase II data set ‣ Pre-IND meeting completed with FDA ‣ Le
Slide 23: Why Invest in LTR Pharma
Why Invest in LTR Pharma Clinical proof. Contracted partners. Funded to deliver For personal use only Clinical Clear and Efficient Early Validation Capital and Differentiation Regulatory Pathway and U.S. Strategy Strategic Position ‣ SPONTAN / ROXUS ‣ Advancing via the FDA 505(b)(2) ‣ 1,000+ prescri
Slide 24: Contact
For personal use only Contact investors@ltrpharma.com www.ltrpharma.com Authorised for release by the Board of Directors